Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Quarterly results
|
|
Sonnet BioTherapeutics Holdings, Inc. (BURG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 09/28/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/22/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/09/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 08/07/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/07/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/07/2023 |
SC 13G/A
| Markey John reports a 10.7% stake in Sonnet BioTherapeutics Holdings, Inc. |
| 07/28/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 07/28/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/17/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/17/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/07/2023 |
SC 13G/A
| Markey John reports a 9.9% stake in Sonnet BioTherapeutics Holdings, Inc. |
| 06/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [______] Issue Date: [______], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, [______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined her...",
"COMMON STOCK PURCHASE WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [______] Issue Date: [______], 2023 Initial Exercise Date: [_______] 1 , 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on [______], 20[__] 2 but not thereafter, to subscribe for and purchase from Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized term...",
"PLACEMENT AGENT WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [______] Issue Date: [______], 2023 Initial Exercise Date: [______] 1 , 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, [______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on [______], 20[__] 2 but not thereafter, to subscribe for and purchase from Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is being issued purs...",
"Sonnet BioTherapeutics Holdings, Inc. 100 Overlook Center, Suite 102 Princeton, New Jersey 08540",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 28, 2023, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , as to the Shares, the Prefunded Warrants and Prefunded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D promulgated thereunder as to the Common Warrants , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the ...",
"Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement" |
|
| 06/30/2023 |
SC 13G
| Markey John reports a 8.5% stake in Sonnet BioTherapeutics Holdings, Inc. |
| 06/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 06/12/2023 |
SC 13G
| Markey John reports a 9.9% stake in Sonnet BioTherapeutics Holdings, Inc. |
| 06/09/2023 |
SC 13G
| Ruck Matthew J reports a 5.6% stake in Sonnet BioTherapeutics Holdings, Inc. |
| 05/26/2023 |
SC 13G/A
| Markey John reports a 8.4% stake in Sonnet BioTherapeutics Holdings, Inc. |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/13/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
|
|
|